Abstract
There is an increasing interest in guiding hit optimization by considering the target binding kinetics of ligands. However, compared to conventional structure-activity relationships, structure-kinetics relationships have not been as thoroughly explored, even for well-studied archetypical drug targets such as the histamine H1 receptor (H1R), a member of the family A G-protein coupled receptor. In this study, we show that the binding kinetics of H1R antagonists at the H1R is dependent on the cyclicity of both the aromatic head group and the amine moiety of H1R ligands, the chemotypes that are characteristic for the first-generation H1R antagonists. Fusing the two aromatic rings of H1R ligands into one tricyclic aromatic head group prolongs the H1R residence time for benchmark H1R ligands as well as for tailored synthetic analogues. The effect of constraining the aromatic rings and the basic amines is systematically explored, leading to a coherent series and detailed discussions of structure-kinetics relationships. This study shows that cyclicity has a pronounced effect on the binding kinetics.
Original language | English |
---|---|
Pages (from-to) | 12755-12768 |
Number of pages | 14 |
Journal | ACS Omega |
Volume | 6 |
Issue number | 19 |
Early online date | 7 May 2021 |
DOIs | |
Publication status | Published - 18 May 2021 |
Bibliographical note
Funding Information:We thank Hans Custers for HR-MS measurements and Elwin Janssen for assistance with NMR experiments. Gist Brocades is acknowledged for providing several compounds as gift. This research was financially supported by the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking, K4DD (grant no. 115366) as well as by the China Scholarship Council (CSC) (grant no. 201506270163).
Publisher Copyright:
© 2021 American Chemical Society. All rights reserved.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
Funding
We thank Hans Custers for HR-MS measurements and Elwin Janssen for assistance with NMR experiments. Gist Brocades is acknowledged for providing several compounds as gift. This research was financially supported by the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking, K4DD (grant no. 115366) as well as by the China Scholarship Council (CSC) (grant no. 201506270163).
Funders | Funder number |
---|---|
Innovative Medicines Initiative | |
EU/EFPIA Innovative Medicines Initiative | |
Not added | 115366 |
China Scholarship Council | 201506270163 |